Answers are grounded in this paper and cite their sources.
Amyloidosis is a systemic disorder marked by the deposition of amyloid fibrils, which can infiltrate the myocardium and cardiac valves, potentially affecting procedural outcomes. While its impact on transcatheter aortic valve replacement (TAVR) is documented, limited data exist on patients undergoing Mitral Transcatheter Edge-to-Edge Repair (MTEER). This study investigates the effect of amyloidosis on in-hospital outcomes following MTEER.
No takes yet. Share an insight, caveat, or question.
Souleymane et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: